Search
Search

This resource is designed for researchers and biotechnologists creating advanced solutions for gene synthesis and customization, tailored to advance therapeutic development. Gene synthesis involves the artificial creation of DNA sequences, enabling the accurate construction of genes for research and therapeutic purposes. On this page, you will find information about our gene synthesis services, including custom gene design, optimization, and delivery. Whether you are developing novel gene therapies, engineering proteins, or conducting functional genomics studies, our advanced gene synthesis technologies can help accelerate your research and bring innovative therapies to market.
Synthetic DNA
Synthetic DNA refers to artificially created DNA sequences that are designed and assembled in a laboratory setting, rather than being naturally derived from biological organisms. This technology allows scientists to construct specific genetic sequences with accuracy, enabling the study of gene function, the development of genetically modified organisms, and the creation of novel therapeutic agents. The safety of synthetic DNA depends on its application and adherence to regulatory guidelines. When used in research and therapeutic contexts, synthetic DNA undergoes extensive testing for effectiveness and safety, including assessments for potential off-target effects and unintended consequences. Regulatory bodies, such as the FDA, oversee the development and use of synthetic DNA to ensure it meets stringent safety standards. Overall, synthetic DNA is considered safe when properly designed, tested, and regulated, playing a crucial role in advancing scientific and medical innovations.
Simplify the therapeutic development workflow
In therapeutic research areas such as chimeric antigen receptors (CARs) for T cell therapy, therapeutic monoclonal antibody production, or SARS-CoV-2 DNA or protein vaccines, the fast and reliable production of DNA is critical.
When DNA sequences are required for the purpose of protein production, low yield poses a significant challenge for biotech companies seeking to accelerate their path to the clinic—that’s in addition to the hurdles that accompany the potential need to obtain template DNA from harmful or infectious agents. Factors that can contribute to low protein yield include sequence complexity and length, very high or low GC content, direct or indirect repeats, and long polypurine or polypyrimidine runs.
A traditional PCR-based approach to generating DNA requires many hands-on steps that can be time-consuming, and requires downstream cloning and plasmid preparation.
Even with an optimized sequence in hand, the classic cloning workflow poses further challenges to the therapeutic development workflow, with its many steps from PCR amplification to plasmid preparation (Figure 1).
Figure 1. Traditional PCR and cloning workflow.
Custom gene synthesis circumvents the limitations of PCR-based workflows. With this technique, synthetic biology has made it possible to reliably, safely, and cost-effectively obtain customized DNA constructs with 100% verified sequence accuracy.
A typical gene synthesis workflow begins online, with the design of a DNA construct using online tools or software. The resulting sequence is then broken up into smaller overlapping pieces (typically 200–1,500 bp) that are easier to synthesize from oligonucleotides. The pieces are then assembled and cloned into a vector (basic delivery of gene or expression vector) and the sequence verified.
Advantages of custom gene synthesis for the therapeutic development workflow include:
These advantages, along with the convenience of customizable gene synthesis services, can afford biotech companies a significant edge and accelerate getting a novel therapeutic to market.
Invitrogen GeneArt Gene Synthesis services were designed to tackle sequences both simple and complex. Our peer-reviewed GeneOptimizer algorithm utilizes a multifactorial approach (up to 20 parameters) beyond just traditional codon optimization, to significantly improve protein expression when it comes wild-type protein—crucial especially for monoclonal antibody development research [2] (Figure 2). You have the option to choose from more than 30 available expression vectors or upload your own to our easy-to-use online portal.
You can also outsource your entire workflow with GeneArt Gene-to-Protein Services. Starting with an electronic nucleotide sequence, you can receive highly purified protein in expression systems, such as mammalian and insect. These GeneArt services leverage highly-advanced Gibco transient expression systems and, coupled with gene optimization, provide a complete, hands-off solution to protein production and purification.
Figure 2. Gene optimization with the GeneOptimizer algorithm significantly increases protein production.
Watch this webinar to learn more about the end-to-end process of our gene-to-protein services
The full suite of Thermo Fisher Scientific DNA and protein services offers researchers the unique opportunity to get their novel therapeutic into the clinic faster.
Find the right custom service to fit your gene synthesis needs
仅供科研使用,不可用于诊断目的。
仅供科研使用,不可用于诊断目的。

